RemeGen Co (688331.SS) Hisse Fiyat

RemeGen Co Ltd is a CN-based company operating in Biotechnology industry. The company is headquartered in Yantai, Shandong and currently employs 3,332 full-time employees. The company went IPO on 2020-11-09. RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The firm is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The firm's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The firm's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The firm mainly conducts its businesses in the domestic market.